Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
about
From tissue to molecular phenotyping: pre-analytical requirements heidelberg experienceInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaMolecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue.Improving molecular testing and personalized medicine in non-small-cell lung cancer in OntarioEstablishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsyA pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR geneEffects of a Multidisciplinary Approach to Improve Volume of Diagnostic Material in CT-Guided Lung Biopsies.Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationFeasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.Thymic neoplasm: a rare disease with a complex clinical presentationUtility of Cell-Block of Bronchial Washings in Diagnosis of Lung Cancer- A Comparative Analysis with Conventional Smear Cytology.The impact of genomic changes on treatment of lung cancer.Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.CT-guided transthoracic core needle biopsy for small pulmonary lesions: diagnostic performance and adequacy for molecular testing.Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial.Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Updates in percutaneous lung biopsy: new indications, techniques and controversies.EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.Helical-Tip Needle for Transthoracic Percutaneous Image-Guided Biopsy of Lung Tumors: Results of a Pilot Prospective Comparative Study with a Standard Tru-Cut Needle.The Role of Interventional Oncology in the Management of Lung Cancer.Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.Computed tomography-guided cutting needle pleural biopsy: Accuracy and complications.Practice Pattern of Transthoracic Needle Biopsy: 2016 Survey in the Members of Korean Society of Thoracic Radiology.Tissue adequacy for ancillary studies beyond frozen section: a potential method for improving diagnostic and therapeutic results.Accuracy of Cytology Specimen and Needle Core Biopsies for Detection of KRAS Mutation in Non-Small Cell Carcinoma: Comparison With Resection Specimen.Comparison of lung lesion biopsies between low-dose CT-guided and conventional CT-guided techniques.Determining the Optimal Number of Core Needle Biopsy Passes for Molecular Diagnostics.The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI.EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
P2860
Q26864637-06E66BE9-6196-47A6-AD8F-691ED1307274Q28303718-7FB88408-164D-4585-B7B9-561504C7F80CQ31043717-16C1D6EC-E7FD-4AC8-9521-F396821D4C93Q33611088-BADDC18D-B08B-4911-AEC5-80486BA12A1FQ33821373-46D28D6D-2C92-4595-BCC1-E2798AD54045Q34134408-7F1AEF10-7C97-48F8-98B2-F28F4C8D64FCQ34694358-D5BE5232-35BE-4983-8F45-B9B924B834A0Q34762839-D81E8741-B71C-4263-9E3C-4C5CB310EFDEQ35681816-F534FAB1-4CD4-4B61-9ED4-42CC04923C03Q35812150-C02ECA22-F621-48EF-BB81-F621F296D2EBQ35875227-C2450C76-70E8-4007-812C-43B8A59D7022Q36439363-0B7588B8-986D-45F7-8770-D55ABDF9B661Q36615755-CF63B7E6-D2F4-480A-BA53-91F39E6DB2D1Q36753888-7BAF579B-A35A-4AE6-9763-A34F917E8F50Q36898941-5552EE79-AA94-4840-8362-79707CCC3B24Q37304354-1528AC74-A212-405A-B430-29FF41C7EDB3Q37429963-5C8C99D9-E421-448D-B609-65041630BC7BQ37677624-E275E6BA-0569-42B4-826D-7173685936F4Q37702165-8F8318E1-8372-48DE-8988-A26E210B53C6Q37871213-A6550D01-3629-49B0-A9BF-998DFD6251A8Q37890996-28057CE7-9D6D-4487-8D4E-D8743EA2ACD5Q38117105-9E13CD64-E48A-437A-8BB1-5B81B36B8DCCQ38167760-323FCD38-A847-4E3D-95C3-F63E20DA0A8DQ38391135-0765C30E-5B6C-41CD-AD45-4B7C96676F2EQ38801255-97F785D4-38CF-4B82-8F74-4E779ED8CC55Q38996196-B81B279F-8984-420D-8A7A-717338806B09Q38999221-65263819-BB55-4441-9801-BE29CB2FA6E3Q39835396-8DBC80EF-5CE5-4718-B362-4E9418A90B96Q41945494-408F04AA-CCFC-4D68-9D6D-6A78C340799DQ42702580-36F6F12E-B910-48EE-BCEA-101BFCCA73DAQ43413897-8CFACF78-2370-4F2C-9A47-9925258ADBC5Q45328192-E5CDA3B5-D45C-4305-A6C3-5702B31ED722Q46872556-4BD95DDE-D0DD-443B-9327-777AD557ADA9Q47668425-DEA328DB-A9D5-42C0-B92E-0F1A182FCB56Q50050305-35D99485-0E1D-41A7-927A-438B0699D63EQ51019075-F16A598B-D15B-4EBC-8D6B-691C3C87A2D9
P2860
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
@en
type
label
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
@en
prefLabel
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
@en
P2093
P2860
P356
P1476
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
@en
P2093
Mark G Kris
Maureen F Zakowski
Naiyer A Rizvi
Raymond H Thornton
Stephen B Solomon
Valerie W Rusch
P2860
P304
P356
10.2214/AJR.09.2858
P407
P577
2010-01-01T00:00:00Z